Envestnet Asset Management Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Asset Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 91,138 shares of the biopharmaceutical company’s stock after acquiring an additional 10,060 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $64,921,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on REGN shares. Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Stock Up 3.6 %

Shares of NASDAQ:REGN opened at $576.72 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a 50-day moving average price of $665.21 and a 200 day moving average price of $762.01. The company has a market cap of $63.05 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.